<DOC>
	<DOCNO>NCT02886793</DOCNO>
	<brief_summary>Pulmonary arterial hypertension ( PAH ) chronic thromboembolic pulmonary hypertension ( CTEPH ) serious disease poor prognosis despite recent advance . Currently , pulmonary hypertension ( PH ) consider cell proliferative disorder , adequately characterize due lack marker . A good understanding mechanism regulate proliferative disorder allow identification new therapeutic target HP . The objective project identify cell proliferative process severe form PH . Patients PAH ( n=20 ) , CTEPH ( n=20 ) healthy control ( n=20 ) undergo characterization microRNAs ( miRNAs ) contain within circulate microparticles ( MPs ) analysis mitochondrial functionality FDG-PET compare cell metabolism lung right ventricle patient control .</brief_summary>
	<brief_title>Cell Proliferation Pulmonary Hypertension . FDG-PET Comparison Between Patients Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>1 . Patients PAH : Hemodynamic diagnosis precapillary pulmonary hypertension : PAPm ≥25 mmHg , PCWP ≤15 mmHg Exclusion group 2,3,4 5 2 . Patients CTEPH : Hemodynamic diagnosis precapillary pulmonary hypertension : PAPm ≥25 mmHg , PCWP ≤15 mmHg Persistence thrombotic perfusion defect pulmonary scintigraphy angioCT , 3 month correct anticoagulant therapy 3 . Healthy subject No known disease condition Normal lung function , chest xray , EKG blood chemistry haematology Severe comorbidity . Pulmonary , pleural rib cage disease interfere FDGPET acquisition Malignancy exception basocellular carcinoma Current smoker former smoker ( last 10 year 10yearpack ) . Pregnant lactate woman Hyperglycemia ( fast 200 mg/dL ) Hypersensitivity product excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>